milrinone has been researched along with cilostazol in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hidaka, H; Inoue, Y; Kimura, Y; Sudo, T; Tachibana, K; Tochizawa, S; Toga, K | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Bruzzese, D; Di Braccio, M; Fossa, P; Grossi, G; Leoncini, G; Mosti, L; Piras, D; Roma, G; Signorello, MG | 1 |
| Alfei, S; Cichero, E; Damonte, G; Di Braccio, M; Fossa, P; Grossi, G; Leoncini, G; Signorello, MG | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arita, M; Dohi, K; Kiyosue, T; Matsui, K; Wang, JC | 1 |
| Cone, J; Fong, M; Kambayashi, J; Liu, Y; Sakurai, K; Sun, B; Tandon, N; Wang, S; Yoshitake, M | 1 |
| Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M | 1 |
| Cone, J; Fong, M; Liu, Y; Wang, S; Yoshitake, M | 1 |
| Colman, RW; Ke, H; Zhang, W | 1 |
| Cone, J; Fong, M; Hensley, J; Kambayashi, J; Liu, Y; Movsesian, MA; Shakur, Y; Yoshitake, M | 1 |
| Clancy, JP; Cobb, BR; Fan, L; Kovacs, TE; Sorscher, EJ | 1 |
| Ikomi, F; Nakamura, K; Ohhashi, T | 1 |
| Guan, Q; Montrose, DC; Quilley, J; Rajagopalan, S; Smith, CJ; Zhao, H | 1 |
| Colman, RW; Zhang, W | 1 |
| Adderley, S; Bowles, EA; Hanson, MS; Sprague, RS; Sridharan, M; Stephenson, AH | 1 |
| Fong, M; Kambayashi, J; Liu, Y; Yoshitake, M | 1 |
| Hashimoto, K; Ishima, T | 1 |
| Baek, AE; Kanthi, Y; Liao, H; Pinsky, DJ; Sutton, NR | 1 |
| Antzelevitch, C; Koncz, I; Szél, T | 1 |
| Chang, NC; Lee, TM; Lin, SZ | 1 |
| Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B | 1 |
| Antzelevitch, C; Barajas-Martinez, H; Gurabi, Z; Hu, D; Koncz, I; Patocskai, B | 1 |
1 review(s) available for milrinone and cilostazol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for milrinone and cilostazol
| Article | Year |
|---|---|
Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Adenylyl Cyclase Inhibitors; Blood Platelets; Calcium; Calcium Signaling; Cilostazol; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cytoskeleton; Enzyme Activation; Hemostatics; Humans; Hydrolysis; Milrinone; Phosphodiesterase Inhibitors; Phosphoprotein Phosphatases; Phosphorylation; Platelet Activation; Protein Phosphatase 1; Proto-Oncogene Proteins c-akt; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Tetrazoles; Thrombin | 2007 |
21 other study(ies) available for milrinone and cilostazol
| Article | Year |
|---|---|
Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Blood Platelets; Cells, Cultured; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; Isoenzymes; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinolines; Quinolones; Recombinant Proteins; Semicarbazides; Urea | 2000 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosp
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Catalytic Domain; Coumarins; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; In Vitro Techniques; Models, Molecular; Morpholines; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors | 2007 |
Synthesis, in vitro antiplatelet activity and molecular modelling studies of 10-substituted 2-(1-piperazinyl)pyrimido[1,2-a]benzimidazol-4(10H)-ones.
Topics: Benzimidazoles; Blood Platelets; Crystallography, X-Ray; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Platelet Aggregation Inhibitors; Pyrimidinones; Reference Values; Structure-Activity Relationship | 2013 |
Effects of pimobendan on the L-type Ca2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone, and cilostazol.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Calcium Channels; Cardiotonic Agents; Cilostazol; Guinea Pigs; Heart Ventricles; In Vitro Techniques; Milrinone; Myocardial Contraction; Papillary Muscles; Patch-Clamp Techniques; Phosphodiesterase Inhibitors; Pyridazines; Tetrazoles | 1999 |
Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
Topics: Animals; Blood Platelets; Cilostazol; Collagen; Coronary Vessels; Cyclic AMP; Dose-Response Relationship, Drug; Heart Ventricles; Humans; In Vitro Techniques; Male; Milrinone; Muscle, Smooth, Vascular; Myocardial Contraction; Perfusion; Platelet Aggregation Inhibitors; Rabbits; Tetrazoles; Vasodilator Agents | 1999 |
Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
Topics: Adenosine; Animals; Blood Pressure; Cilostazol; Dose-Response Relationship, Drug; Heart Rate; Humans; Intermittent Claudication; Male; Milrinone; Myocardial Ischemia; Pentoxifylline; Phosphodiesterase Inhibitors; Rabbits; Tetrazoles; Thioinosine | 2000 |
Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Animals; Cilostazol; Contraindications; Cyclic Nucleotide Phosphodiesterases, Type 3; Heart; Hemodynamics; In Vitro Techniques; Male; Milrinone; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Rabbits; Tetrazoles; Vasodilator Agents | 2001 |
Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Binding Sites; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; Milrinone; Models, Molecular; Mutagenesis, Site-Directed; Phosphodiesterase Inhibitors; Tetrazoles | 2002 |
Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Calcium; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Interactions; Heart; Humans; Isoenzymes; Milrinone; Myocardium; Myocytes, Cardiac; Phosphodiesterase Inhibitors; Rabbits; Rolipram; Tetrazoles; Tissue Distribution | 2002 |
Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells.
Topics: Adenosine Deaminase; Anions; Cell Line; Chlorine; Cilostazol; Colforsin; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Electrophysiology; Epithelium; Glyburide; Humans; Hypoglycemic Agents; Milrinone; Mutation; Papaverine; Phosphodiesterase Inhibitors; Piperazines; Purines; Receptors, Purinergic P1; Rolipram; Sildenafil Citrate; Sulfones; Tetrazoles; Time Factors | 2003 |
Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arterioles; Aspirin; Cerebrovascular Circulation; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclooxygenase Inhibitors; Drug Interactions; Endothelium, Vascular; Enzyme Inhibitors; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Male; Milrinone; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroprusside; Phosphodiesterase Inhibitors; Pressure; Prostaglandins; Rabbits; Tetrazoles; Vasodilation; Vasodilator Agents | 2006 |
Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angioplasty, Balloon; Animals; Aorta; Carboxylic Acids; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Male; Milrinone; Nitriles; Phosphodiesterase Inhibitors; Phosphorylation; Quinolones; Rats; Rats, Sprague-Dawley; Tetrazoles; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2007 |
Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP.
Topics: Adult; Aged; Animals; Blotting, Western; Cilostazol; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 3; Drug Interactions; Erythrocyte Membrane; Female; Humans; Iloprost; Male; Middle Aged; Milrinone; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Quinolones; Rabbits; Tetrazoles; Up-Regulation | 2008 |
Cilostazol increases tissue blood flow in contracting rabbit gastrocnemius muscle.
Topics: Adenosine; AMP Deaminase; Animals; Cilostazol; Dose-Response Relationship, Drug; Electric Stimulation; Male; Milrinone; Models, Animal; Muscle Contraction; Muscle, Skeletal; Phosphodiesterase 3 Inhibitors; Piperazines; Rabbits; Regional Blood Flow; Tetrazoles; Vasodilator Agents | 2010 |
Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol.
Topics: Animals; Cilostazol; Drug Synergism; Inositol 1,4,5-Trisphosphate Receptors; JNK Mitogen-Activated Protein Kinases; Milrinone; Mitogen-Activated Protein Kinase Kinases; Nerve Growth Factor; Neurites; PC12 Cells; Peptide Elongation Factor 1; Phosphatidylinositol 3-Kinases; Phosphodiesterase 3 Inhibitors; Phosphoinositide-3 Kinase Inhibitors; Phospholipase C gamma; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolones; raf Kinases; ras Proteins; Rats; Receptor, trkA; Signal Transduction; Tetrazoles | 2011 |
Regulation of ecto-apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3).
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenosine Triphosphatases; Antigens, CD; Apyrase; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Human Umbilical Vein Endothelial Cells; Humans; Macrophages; Milrinone; Tetrazoles; Transcription, Genetic; Ubiquitination | 2013 |
Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome.
Topics: Action Potentials; Animals; Brugada Syndrome; Cilostazol; Disease Models, Animal; Dogs; Drug Therapy, Combination; Heart Conduction System; Heart Rate; Milrinone; Phosphodiesterase 3 Inhibitors; Tetrazoles | 2013 |
Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts.
Topics: Animals; Cilostazol; Heart; Male; Milrinone; Myocardial Infarction; Phosphodiesterase 3 Inhibitors; Rats; Rats, Wistar; Sympathetic Nervous System; Tetrazoles | 2014 |
Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cilostazol; Disease Models, Animal; Dogs; Electrocardiography; Heart Conduction System; Hypothermia, Induced; Milrinone; Perfusion; Phosphodiesterase 3 Inhibitors; Quinidine; Signal Transduction; Tachycardia, Ventricular; Tetrazoles; Time Factors; Ventricular Fibrillation | 2014 |
Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome.
Topics: Action Potentials; Animals; Cardiac Electrophysiology; Cardiovascular Agents; Cilostazol; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Electrocardiography; Ion Channels; Isoproterenol; Milrinone; Tachycardia, Ventricular; Tetrazoles; Ventricular Fibrillation | 2016 |